Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

doi:10.6004/jnccn.2016.0169

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Dec 2016

Mesa Ruben, Jamieson Catriona, Bhatia Ravi, Deininger Michael W, Gerds Aaron T, Gojo Ivana, Gotlib Jason, Gundabolu Krishna, Hobbs Gabriela, Klisovic Rebecca B, Kropf Patricia, Mohan Sanjay R, Oh Stephen, Padron Eric, Podoltsev Nikolai, Pollyea Daniel A, Rampal Raajit, Rein Lindsay A M, Scott Bart, Snyder David S, Stein Brady L, Verstovsek Srdan, Wadleigh Martha, Wang Eunice S, Bergman Mary Anne, Gregory Kristina M, Sundar Hema

Abstract excerpt

Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Thrombocythemia, Essential

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Calreticulin

Share to Medical Oncology

Share to Philadelphia Chromosome

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Quality of Life

Share to Receptors, Thrombopoietin

Source

Open in PubMed

Identifiers

PMID: 27956542
DOI: 10.6004/jnccn.2016.0169

Genes

CALR
JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.PMID 27956542Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Guidelines for the management of myeloproliferative neoplasms.Semantic proximity Read ↗

[CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?]Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Current approaches to challenging scenarios in myeloproliferative neoplasms.Semantic proximity Read ↗

Update from the latest WHO classification of MPNs: a user's manual.Semantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemiaSemantic proximity Read ↗

Biology and Current Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm VariantsSemantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasmsSemantic proximity Read ↗

Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.